FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 351:1254-1256 September 16, 2004 Number 12 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

A large number of genetic mutations that cause muscular dystrophies have been identified. Most forms of muscular dystrophy are caused by mutations that result in protein deficiencies. This knowledge has led to the hope that a cure will be just around the corner in the form of gene therapy. Unfortunately, gene therapy has proved to be a much larger challenge than generally appreciated even a decade ago. There has thus been an increased focus on alternative approaches to the treatment of muscular dystrophies in recent years. Specifically, several groups have evaluated ways to bypass, rather than correct, the genetic defects . . . [Full Text of this Article]

Source Information

From the Department of Neurology and Neurological Sciences, Stanford University, and the Neurology Service, Veterans Affairs Palo Alto Health Care Systems, Palo Alto — both in California.

This article has been cited by other articles:

• Boito, C. A., Melacini, P., Vianello, A., Prandini, P., Gavassini, B. F., Bagattin, A., Siciliano, G., Angelini, C., Pegoraro, E. (2005). Clinical and Molecular Characterization of Patients With Limb-Girdle Muscular Dystrophy Type 2I. Arch Neurol 62: 1894-1899 [Abstract] [Full Text]